Article
Ductal pancreatic cancer interception by FGFR2 abrogation
2024-10-18
Abstract excerpt
<h4>ABSTRACT</h4> Activating KRAS mutations are a key feature of pancreatic ductal adenocarcinoma (PDA) and drive tumor initiation and progression. However, mutant KRAS by itself is weakly oncogenic. The pathways that cooperate with mutant KRAS to induce tumorigenesis are less-defined. Analyzing organoids and murine and human pancreatic specimens, we found that the receptor tyrosine kinase FGFR2 was progressively...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 382cc711-6bcd-58f4-827b-f206175c01a0
- DOI
- 10.1101/2024.10.16.618726
